What Is Semaglutide? How It Works, What Research Shows, and How It Compares to Other GLP-1s

Semaglutide is a GLP-1 receptor agonist — a synthetic version of the gut hormone glucagon-like peptide-1 that binds to GLP-1 receptors in the pancreas, brain, and gut. It stimulates insulin secretion when blood sugar is elevated, suppresses glucagon, slows gastric emptying, and acts on hypothalamic appetite centers to reduce hunger. Originally developed for type 2 diabetes (brand name Ozempic), it was later approved at a higher dose for chronic weight management (Wegovy). The drug's long half-life of approximately 7 days allows once-weekly dosing, which is a key pharmacokinetic advantage over older GLP-1 agonists.

GLP-1 is a hormone your gut naturally produces after eating. It does several things simultaneously: tells the pancreas to release insulin (but only when glucose is elevated, which is a critical safety feature), tells the pancreas to stop releasing glucagon (which otherwise raises blood sugar), slows gastric emptying so food leaves the stomach more gradually, and signals satiety centers in the hypothalamus so you feel full sooner and stay full longer. Natural GLP-1 has a half-life of about 2 minutes — it gets chopped up by the enzyme DPP-4 almost immediately after release. Semaglutide is engineered to resist DPP-4 degradation. It achieves this through three key structural modifications: an amino acid substitution at position 8 (Aib replaces alanine, blocking DPP-4 cleavage), acylation with a C18 fatty acid chain that binds to albumin in the blood (dramatically extending circulation time), and a small amino acid substitution at position 34 (Arg replaces Lys) that ensures the fatty acid attaches at the correct position. These changes extend the half-life from 2 minutes to approximately 168 hours (7 days), enabling once-weekly dosing. The appetite suppression mechanism deserves special attention because it is the primary driver of weight loss effects. Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the arcuate nucleus and other hypothalamic regions involved in energy homeostasis. Brain imaging studies show reduced activation in reward centers when patients on semaglutide view food images — meaning the drug appears to reduce not just hunger, but the hedonic drive to eat. This dual effect on homeostatic and reward-based eating is likely why semaglutide produces greater weight loss than older GLP-1 agonists that have weaker central nervous system penetration.

The evidence base for semaglutide is extensive. Two major trial programs — SUSTAIN (diabetes) and STEP (obesity) — established the drug's efficacy and safety profile. For type 2 diabetes, the SUSTAIN trials showed that semaglutide 1.0 mg weekly reduced HbA1c by approximately 1.5-1.8 percentage points compared to 0.4-0.5 points for placebo. It also produced 4-6 kg of weight loss as a secondary effect. SUSTAIN-6, a cardiovascular outcomes trial, showed a 26% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo — this was a landmark finding that positioned GLP-1 agonists as cardioprotective, not just glucose-lowering. For obesity, the STEP trials tested semaglutide 2.4 mg weekly (the higher dose used in Wegovy). STEP-1 enrolled adults with BMI of 30 or greater (or 27+ with a weight-related comorbidity) without diabetes. At 68 weeks, the semaglutide group lost an average of 14.9% of body weight compared to 2.4% for placebo. About one-third of participants lost 20% or more of their body weight. For context, most previous anti-obesity drugs produced 3-7% weight loss above placebo. STEP-3 added behavioral therapy, and STEP-4 examined what happens when you stop the drug (weight regain was significant — about two-thirds of lost weight returned within one year of discontinuation). This finding is important: semaglutide appears to require ongoing use to maintain weight loss, similar to how blood pressure medication requires ongoing use to maintain pressure control. The weight regain data has significant implications for anyone considering this drug class.

The most common side effects are gastrointestinal: nausea (reported by 20-44% of participants across trials), vomiting, diarrhea, and constipation. These effects are dose-dependent and typically worst during the dose-escalation phase. Most patients see improvement after 4-8 weeks at a stable dose. Slow titration schedules (increasing the dose every 4 weeks rather than every 2) significantly reduce nausea incidence. More serious but less common risks include pancreatitis (rare but observed at higher rates than placebo in some trials), gallbladder events (gallstones form more frequently during rapid weight loss, regardless of the method), and a theoretical concern about medullary thyroid carcinoma based on rodent studies — this led to a boxed warning, though no confirmed human cases have been attributed to semaglutide in clinical trials or post-marketing surveillance. Muscle loss during weight loss is an important consideration that gets less attention than it should. In STEP-1, about 39% of total weight lost was lean mass (muscle). This is consistent with weight loss from any cause, but it means someone losing 15% of body weight might lose meaningful muscle. Resistance training and adequate protein intake are strongly recommended during GLP-1 therapy to preserve lean mass. Some researchers are investigating whether newer dual-agonist drugs produce more favorable fat-to-muscle loss ratios. This content is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting any medication or protocol.

Liraglutide (Saxenda/Victoza) was the first GLP-1 agonist approved for obesity, but it requires daily injection and produces less weight loss — about 8% in the SCALE trials versus 15% for semaglutide in STEP. Liraglutide's half-life is approximately 13 hours compared to semaglutide's 168 hours, which explains the daily dosing requirement. For patients who want to start with a less potent option or who cannot tolerate semaglutide's side effect profile, liraglutide remains a reasonable alternative. Tirzepatide (Mounjaro/Zepbound) is a newer entrant that acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The SURMOUNT trials showed tirzepatide 15 mg produced approximately 20-22% weight loss at 72 weeks — meaningfully more than semaglutide's 15% in head-to-head comparisons. The SURPASS trials for diabetes also showed superior HbA1c reduction. Tirzepatide is dosed weekly, like semaglutide, but its dual mechanism appears to provide incremental efficacy. The GI side effect profile is broadly similar. Oral semaglutide (Rybelsus) uses an absorption enhancer (SNAC) to survive the stomach and get absorbed through the gastric lining. Bioavailability is only about 1%, so the oral dose (14 mg daily) is much higher than the injected dose to achieve similar blood levels. It must be taken on an empty stomach with no more than 4 oz of water, and the patient must wait 30 minutes before eating. The convenience advantage of a pill is offset by the strict dosing requirements and somewhat lower efficacy compared to injected semaglutide. Dosed supports protocol tracking for all GLP-1 agonists including dose titration schedules, injection site rotation logging, and half-life-aware reminder timing for both weekly and daily dosing patterns.